Research
Systematic analysis of regulatory precedents and emerging compliance patterns for innovators.
Research ReportMay 5, 2026
What FDA's Latest mRNA Approvals Tell Us About CMC Expectations
Two mRNA/LNP approvals in Q1 2026 revealed a consistent pattern in how FDA reviewers are evaluating analytical data packages. We extracted the key Chemistry Review signals and what they mean for teams preparing IND submissions this year.
B
Beacon Compliance TeamResearch ReportApril 21, 2026
The Hidden Cost of a 30-Day IND Delay
A one-month delay in IND submission doesn't just push back your clinical timeline — it compounds. We modelled the downstream cost impact across program length, trial phases, and revenue timing.
B
Beacon Compliance Team